Drug Profile
Research programme: sodium glucose co-transporter inhibitors - sanofi-aventis
Alternative Names: SAR 474832Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Sodium-glucose transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France
- 28 Sep 2005 Preclinical trials in Type-2 diabetes mellitus in France (unspecified route)